Citations

Mayo Clinic

Showing 10 of 108551 citations.

Primary Pulmonary Myxoid Sarcoma and Thoracic Angiomatoid Fibrous Histiocytoma
Kerper, Allison L. , Larsen, Brandon T. , Folpe, Andrew L. , Roden, Anja C. , Torres‐Mora, Jorge , Aubry, Marie‐Christine, Kerper, Allison , Boland, Jennifer M. , Lo, Ying‐Chun , Aubry, Marie-Christine

American Journal of Surgical Pathology | February 26, 2024 | Volume: 48 | Issue: 5 | Pages: 562-569

10.1097/pas.0000000000002189 | PMID 38407279 Get It

Primary pulmonary myxoid sarcoma (PPMS) and thoracic angiomatoid fibrous histiocytoma (AFH) are rare neoplasms with EWSR1 fusions and overlapping morphology. Both tumor types often show epithelial membrane antigen expression, but AFH characteristically co-expresses desmin. We encountered a case of PPMS with the unexpected finding of patchy, strong anaplastic lymphoma kinase (ALK) (previously reported in AFH) and synaptophysin expression. We evaluated a cohort of PPMS and thoracic AFH with systematic morphologic comparison and surveyed for aberrant expression of ALK and synaptophysin. Medical records and slides were reviewed for 16 molecularly confirmed cases of PPMS (n=5) and thoracic AFH (n=11). Each case was scored for morphologic characteristics typical of PPMS and/or AFH. ALK, synaptophysin, chromogranin, desmin, and epithelial membrane antigen immunostains were performed on cases with available tissue. AFH and PPMS cases showed similar age at presentation and long-term tumor behavior. Almost all cases of PPMS and AFH had a fibrous pseudocapsule and lymphoid rim. All PPMS had myxoid stroma and reticular growth pattern, but these features were also present in a subset of AFH. Synaptophysin expression was present in 6 of 11 AFH and 1 of 5 PPMS; all tested cases were negative for chromogranin (n=15). One case of AFH and 1 case of PPMS showed focally strong coexpression of synaptophysin and ALK. AFH and PPMS show considerable clinicopathologic overlap. When supportive, the immunohistochemical findings described may aid in diagnosis before molecular confirmation. PPMS and AFH may be morphologic variants of the same clinicopathologic entity, which can show more immunophenotypic variability than previously reported.
Intermittent fasting regimens for metabolic dysfunction-associated steatotic liver disease: a systematic review and network meta-analysis of randomized controlled trials
Naeem, Ahmed, Khlidj, Yehya , Tanashat, Mohammad , Suilik, Husam Abu , Altobaishat, Obieda , Abdelnabi, Mohamed , Katamesh, Basant E. , Khlidj, Yehya , Abuelazm, Mohamed , Mohamed, Islam , Suilik, Husam Abu , Abdelazeem, Basel

European Journal of Gastroenterology & Hepatology | February 26, 2024 | Volume: 36 | Issue: 4 | Pages: 371-381

10.1097/meg.0000000000002715 | PMID 38407890 Get It

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent metabolic disorder characterized by excessive hepatic fat accumulation. Intermittent fasting (IF) has emerged as a potential therapeutic strategy with the ability to induce weight loss, improve insulin sensitivity and reduce hepatic steatosis. We aim to compare the efficacy of different IF regimens for MASLD management. A systematic review and network meta-analysis of randomized controlled trials investigating different IF regimens for MASLD. PubMed, EMBASE, WOS, SCOPUS and Cochrane Central Register of Controlled Trials were searched until 10 April 2023. Analysis was performed using R software with the meta and netmeta packages. Mean difference (MD) was used to pool continuous outcomes with 95% confidence intervals (CIs). Our meta-analysis was registered in PROSPERO (CRD42023418467). Our meta-analysis included eight randomized controlled trials with a total of 635 participants. The 5 : 2 diet significantly improved liver stiffness (MD, −0.32; 95% CI, −0.55 to −0.09; P < 0.01). Time-restricted feeding significantly improved liver steatosis (controlled attenuation parameter score) (MD, −39.83; 95% CI, −64.78 to −14.87; P < 0.01). No significant changes were observed in asparate aminotransferase, gamma-glutamyl transpeptidase, low-density lipoproteins cholesterol, total cholesterol, triglyceride levels, basal metabolic index, blood pressure, Homeostatic Model Assessment of Insulin Resistance, fasting blood sugar, lean body mass or waist circumference across all IF regimens. However, alternate-day fasting showed positive results in anthropometric measures, including significant improvements in lean body mass, waist circumference, fat mass and weight reduction (P < 0.05). IF regimens showed various positive effects on clinical outcomes in MASLD patients; however, these effects were not consistent. Therefore, a patient-tailored IF regimen should be considered.
Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy
Qin, Kang , Li, Shenduo , Hong, Lingzhi , Padmakumar, Priyadharshini, Waree, Rinsurongkawong, Le, Xiuning , Vokes, Natalie I. , Vaporciyan, Ara A. , Lee, J. Jack , Jaffray, David A. , Altan, Mehmet , Lou, Yanyan , Zhang, Jianjun , Hong, Lingzhi , Le, Xiuning , Lee, J Jack , Zhang, Jianjun , Wang, Kaiwen , Hubert, Shawna Marie , Rai, Kunal , Gibbons, Don L , Heymach, John V. , Woodman, Scott Eric , Chung, Caroline , Vokes, N.

Cancers | February 26, 2024 | Volume: 16 | Issue: 5 | Pages: 935

10.3390/cancers16050935 | PMID 38473297 Get It

Docetaxel +/− ramucirumab remains the standard-of-care therapy for patients with metastatic non-small-cell lung cancer (NSCLC) after progression on platinum doublets and immune checkpoint inhibitors (ICIs). The aim of our study was to investigate whether the cancer gene mutation status was associated with clinical benefits from docetaxel +/− ramucirumab. We also investigated whether platinum/taxane-based regimens offered a better clinical benefit in this patient population. A total of 454 patients were analyzed (docetaxel +/− ramucirumab n=381; platinum/taxane-based regimens n=73). Progression-free survival (PFS) and overall survival (OS) were compared among different subpopulations with different cancer gene mutations and between patients who received docetaxel +/− ramucirumab versus platinum/taxane-based regimens. Among patients who received docetaxel +/− ramucirumab, the top mutated cancer genes included TP53 (n=167), KRAS (n=127), EGFR (n=65), STK11 (n=32), ERBB2 (HER2) (n=26), etc. None of these cancer gene mutations or PD-L1 expression was associated with PFS or OS. Platinum/taxane-based regimens were associated with a significantly longer mQS (13.00 m, 95% Cl: 11.20–14.80 m versus 8.40 m, 95% Cl: 7.12–9.68 m, LogRank P=0.019) than docetaxel +/− ramcirumab. Key prognostic factors including age, histology, and performance status were not different between these two groups. In conclusion, in patients with metastatic NSCLC who have progressed on platinum doublets and ICIs, the clinical benefit from docetaxel +/− ramucirumab is not associated with the cancer gene mutation status. Platinum/taxane-based regimens may offer a superior clinical benefit over docetaxel +/− ramucirumab in this patient population.
Maternal and child life years gained by transfusing low titer group O whole blood in trauma: A computer simulation
Yazer, Mark H. , Leeper, Christine M. , Spinella, Philip C. , Emery, Stephen P. , Horvath, Sarah , Seheult, Jansen N. , Leeper, Christine , Spinella, Philip C , Seheult, Jansen N

Transfusion | February 26, 2024 | Volume: 64 | Issue: S2 | Pages: No page available

10.1111/trf.17767 | PMID 38404198 Get It

AbstractBackgroundUsing low titer group O whole blood (LTOWB) is increasingly popular for resuscitating trauma patients. LTOWB is often RhD‐positive, which might cause D‐alloimmunization and hemolytic disease of the fetus and newborn (HDFN) if transfused to RhD‐negative females of childbearing potential (FCP). This simulation determined the number of life years gained by the FCP and her future children if she was resuscitated with LTOWB compared with conventional component therapy (CCT).MethodsThe model simulated 500,000 injured FCPs of each age between 0 and 49 years with LTOWB mortality relative reductions (MRRs) compared with components between 0.1% and 25%. For each surviving FCP, number of life years gained was calculated using her age at injury and average life expectancy for American women. The number of expected future pregnancies for FCPs that did not survive was also based on her age at injury; each future child was assigned the maximum lifespan unless they suffered perinatal mortality or serious neurological events from HDFN.ResultsThe LTOWB group with an MRR 25% compared with CCT had the largest total life years gained. The point of equivalence for RhD‐positive LTOWB compared to CCT, where life years lost due to severe HDFN was equivalent to life years gained due to FCP survival/future childbearing, occurred at an MRR of approximately 0.1%.ConclusionIn this model, RhD‐positive LTOWB resulted in substantial gains in maternal and child life years compared with CCT. A >0.1% relative mortality reduction from LTOWB offset the life years lost to HDFN mortality and severe neurological events.
Repeated attacks of hereditary angioedema in pediatric female
Abass, Maha Khalil , Dabosy, Abdelaly, Khawaja, Khulood , Fischer, Philip R.

Paediatrics and International Child Health | February 26, 2024 | Volume: 44 | Issue: 1 | Pages: 39-41

10.1080/20469047.2024.2317488 | PMID 38404177 Get It

Global analysis of urinary extracellular vesicle small RNAs in autosomal dominant polycystic kidney disease
Ali, Hamad , Malik, Md. Zubbair , Abu‐Farha, Mohamed , Jacob, Sindhu, Bahbahani, Yousif , Naim, Medhat, Alsayegh, Mohammad Y., Ong, Albert , Harris, Peter C. , Harris, Peter C , Ong, Albert C M , Abubaker, Jehad Ahmed , Cherian, Preethi , Nizam, Rasheeba , Ahmad, Sajjad , Thanaraj, Thangavel Alphonse , Al‐Mulla, Fahd

The Journal of Gene Medicine | February 26, 2024 | Volume: 26 | Issue: 2 | Pages: No page available

10.1002/jgm.3674 | PMID 38404150 Get It

AbstractBackgroundAutosomal dominant polycystic kidney disease (ADPKD) is the most prevalent monogenic renal disease progressing to end‐stage renal disease. There is a pressing need for the identification of early ADPKD biomarkers to enable timely intervention and the development of effective therapeutic approaches. Here, we profiled human urinary extracellular vesicles small RNAs by small RNA sequencing in patients with ADPKD and compared their differential expression considering healthy control individuals to identify dysregulated small RNAs and analyze downstream interaction to gain insight about molecular pathophysiology.MethodsThis is a cross‐sectional study where urine samples were collected from a total of 23 PKD1‐ADPKD patients and 28 healthy individuals. Urinary extracellular vesicles were purified, and small RNA was isolated and sequenced. Differentially expressed Small RNA were identified and functional enrichment analysis of the critical miRNAs was performed to identify driver genes and affected pathways.ResultsmiR‐320b, miR‐320c, miR‐146a‐5p, miR‐199b‐3p, miR‐671‐5p, miR‐1246, miR‐8485, miR‐3656, has_piR_020497, has_piR_020496 and has_piR_016271 were significantly upregulated in ADPKD patient urine extracellular vesicles and miRNA‐29c was significantly downregulated. Five ‘driver’ target genes (FBRS, EDC3, FMNL3, CTNNBIP1 and KMT2A) were identified.ConclusionsThe findings of the present study make significant contributions to the understanding of ADPKD pathogenesis and to the identification of novel biomarkers and potential drug targets aimed at slowing disease progression in ADPKD.
Pulmonary Biodistribution of Platelet-Derived Regenerative Exosomes in a Porcine Model
Rizzo, Skylar A. , Bagwell, Monique S , Schiebel, Paige , Rolland, Tyler , Mahlberg, Ryan , Witt, Tyra A. , Nagel, Mary, Stalboerger, Paul G., Rolland, Tyler J , Mahlberg, Ryan C , Nagel, Mary E, Bagwell, Monique , Nagel, Mary E., Behfar, Atta

International Journal of Molecular Sciences | February 26, 2024 | Volume: 25 | Issue: 5 | Pages: 2642

10.3390/ijms25052642 | PMID 38473889 Get It

The purpose of this study was to evaluate the biodistribution of a platelet-derived exosome product (PEP), previously shown to promote regeneration in the setting of wound healing, in a porcine model delivered through various approaches. Exosomes were labeled with DiR far-red lipophilic dye to track and quantify exosomes in tissue, following delivery via intravenous, pulmonary artery balloon catheter, or nebulization in sus scrofa domestic pigs. Following euthanasia, far-red dye was detected by Xenogen IVUS imaging, while exosomal protein CD63 was detected by Western blot and immunohistochemistry. Nebulization and intravenous delivery both resulted in global uptake of exosomes within the lung parenchyma. However, nebulization resulted in the greatest degree of exosome uptake. Pulmonary artery balloon catheter-guided delivery provided the further ability to localize pulmonary delivery. No off-target absorption was noted in the heart, spleen, or kidney. However, the liver demonstrated uptake primarily in nebulization-treated animals. Nebulization also resulted in uptake in the trachea, without significant absorption in the esophagus. Overall, this study demonstrated the feasibility of pulmonary delivery of exosomes using nebulization or intravenous infusion to accomplish global delivery or pulmonary artery balloon catheter-guided delivery for localized delivery.
Biomechanical Stability of Diaphyseal Ulnar Shaft Fractures and Ulnar Shortening Osteotomies After Fixation
Dittman, Lauren E. , Hooke, Alexander W. , Kakar, Sanjeev , Kakar, Sanjeev , Tagliero, Lauren E , Hinchcliff, Katharine M.

HAND | February 26, 2024 | Volume: 20 | Issue: 4 | Pages: 619-623

10.1177/15589447241233707 | PMID 38406971 Get It

Background: To determine the amount of micromotion during forearm rotation after diaphyseal ulnar shaft fracture or osteotomy. Methods: This was a biomechanical study using 7 paired-matched cadavers. The upper extremity was mounted in a custom rig and the forearm brought through full pronation and supination. A Hall effect sensor was placed at the fracture ends to measure micromotion for all tested conditions. There were 4 conditions tested: (1) intact ulnar shaft with plate to act as a control; (2) transverse fracture/osteotomy without stabilization; (3) fracture/osteotomy with cortical apposition stabilized with plate fixation; and (4) 50% comminuted fracture stabilized with plate. Results: There was a significantly greater amount of fracture site motion in the fracture/osteotomy model without stabilization compared with all other tested conditions ( P < .001, .0001, .0003, respectively). The fracture/osteotomy site with cortical apposition and the comminuted fracture models showed no statistically significant differences in the amount of micromotion compared with each another ( P = .952) or compared with the intact ulnar shaft ( P = .997, .889, respectively). Conclusions: There was no significant difference in the amount of motion between an intact ulnar shaft, an ulnar shaft fracture with cortical apposition stabilized with a plate, and a plated comminuted fracture. These findings may help surgeons decide on their type of postoperative immobilization in the setting of isolated ulnar shaft fractures or ulnar shaft osteotomies stabilized with plate fixation.
Role of Arrhythmic Phenotype in Prognostic Stratification and Management of Dilated Cardiomyopathy
Setti, Martina , Merlo, Marco , Gigli, Marta , Munaretto, L, Paldino, Alessia , Gava, Carola Pio Loco Detto , Medo, Kristen , Gregorio, Caterina , Graw, Sharon , Castrichini, Matteo , Cannatà, Antonio , Ferro, Matteo Dal , Taylor, Matthew R.G. , Mestroni, Luisa , Mestroni, Luisa , Castrichini, Matteo , Medo, Kristen , Taylor, Matthew R G , Cannatà, Antonio , Gregorio, Caterina , Stolfo, Davide , Luca, Antonio De , Ribichini, Flavio Luciano , Sinagra, Gianfranco

European Journal of Heart Failure | February 26, 2024 | Volume: 26 | Issue: 3 | Pages: 581-589

10.1002/ejhf.3168 | PMID 38404225 Get It

Abstract Aims Dilated cardiomyopathy (DCM) with arrhythmic phenotype combines phenotypical aspects of DCM and predisposition to ventricular arrhythmias, typical of arrhythmogenic cardiomyopathy. The definition of DCM with arrhythmic phenotype is not universally accepted, leading to uncertainty in the identification of high-risk patients. This study aimed to assess the prognostic impact of arrhythmic phenotype in risk stratification and the correlation of arrhythmic markers with high-risk arrhythmogenic gene variants in DCM patients. Methods and results In this multicentre study, DCM patients with available genetic testing were analysed. The following arrhythmic markers, present at baseline or within 1 year of enrolment, were tested: unexplained syncope, rapid non-sustained ventricular tachycardia (NSVT), ≥1000 premature ventricular contractions/24 h or ≥50 ventricular couplets/24 h. LMNA, FLNC, RBM20, and desmosomal pathogenic or likely pathogenic gene variants were considered high-risk arrhythmogenic genes. The study endpoint was a composite of sudden cardiac death and major ventricular arrhythmias (SCD/MVA). We studied 742 DCM patients (45 ± 14 years, 34% female, 410 [55%] with left ventricular ejection fraction [LVEF] &lt;35%). During a median follow-up of 6 years (interquartile range 1.6–12.1), unexplained syncope and NSVT were the only arrhythmic markers associated with SCD/MVA, and the combination of the two markers carried a significant additive risk of SCD/MVA, incremental to LVEF and New York Heart Association class. The probability of identifying an arrhythmogenic genotype rose from 8% to 30% if both early syncope and NSVT were present. Conclusion In DCM patients, the combination of early detected NSVT and unexplained syncope increases the risk of life-threatening arrhythmic outcomes and can aid the identification of carriers of malignant arrhythmogenic genotypes.
Lens and solution properties in patients with and without midday fogging
Fogt, Jennifer Swingle , Nau, Cherie B. , Harthan, Jennifer , Nau, Amy , Patton, Kim, Schornack, Muriel , Nau, Cherie, Schornack, Muriel , Fogt, Jennifer Swingle , Shorter, Ellen , Patton, Kimberly

Ophthalmic and Physiological Optics | February 26, 2024 | Volume: 44 | Issue: 4 | Pages: 769-773

10.1111/opo.13293 | PMID 38404141 Get It

Abstract Introduction Midday fogging is a complication of scleral lens (SL) wear that interrupts clear vision during the course of wear. SLs can be made with a variety of gas permeable materials, sizes and surface treatments, and various solutions are available for storing the lenses and for filling them before application on the eye. Many of these factors have been implicated as possible contributors to midday fogging. This study explored the lens and solution properties in habitual SL wearers with and without midday fogging. Methods In this prospective study, 48 habitual SL wearers were evaluated and asked to report whether they experienced midday fogging and if they removed their lenses during the day. They completed the Ocular Surface Disease Index (OSDI), which is a validated tool for dry eye assessment. Lens parameters (material, coatings and diameter) and lens storage and filling solutions were documented. Backward elimination of regression terms evaluated the lens and solution properties in those with and without fogging. OSDI scores were compared using the Mann–Whitney analysis. Results Collectively, the lens properties and solutions accounted for 27.7% of the variance related to midday fogging. None of the factors alone had a significant impact upon midday fogging. The median (interquartile range) OSDI score for those with fogging [37 (35)] was significantly different from those without fogging [10 (15)], with the scores corresponding to severe dry eye and normal eyes, respectively. Conclusion SL wearers with midday fogging exhibited similar symptoms to patients with severe dry eye. Lens and solution characteristics may play a small role in patients with midday fogging, although changing just a single factor is not likely to impact its presence.